

# Paul J Declerck

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7783939/paul-j-declerck-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

236  
papers

6,043  
citations

41  
h-index

63  
g-index

260  
ext. papers

6,648  
ext. citations

7  
avg, IF

5.86  
L-index

#	Paper	IF	Citations
236	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 820755	4.9	1
235	Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, 988-993	1.5	3
234	Intratumoral DNA-based delivery of checkpoint-inhibiting antibodies and interleukin 12 triggers T cell infiltration and anti-tumor response. <i>Cancer Gene Therapy</i> , <b>2021</b> ,	5.4	2
233	Both plasma basic carboxypeptidases, carboxypeptidase B2 and carboxypeptidase N, regulate vascular leakage activity in mice. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> ,	15.4	1
232	DNA-based delivery of anti-DR5 Nanobodies improves exposure and anti-tumor efficacy over protein-based administration. <i>Cancer Gene Therapy</i> , <b>2021</b> , 28, 828-838	5.4	4
231	A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	20
230	Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	8
229	Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. <i>Journal of Pharmaceutical Policy and Practice</i> , <b>2021</b> , 14, 53	3.2	2
228	Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	2
227	Miniaturized single-cell technologies for monoclonal antibody discovery. <i>Lab on A Chip</i> , <b>2021</b> , 21, 3627-3654	5.4	2
226	Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
225	S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism. <i>Thrombosis Research</i> , <b>2021</b> , 204, 81-87	8.2	0
224	Improved Potency and Safety of DNA-Encoded Antibody Therapeutics Through Plasmid Backbone and Expression Cassette Engineering. <i>Human Gene Therapy</i> , <b>2021</b> , 32, 1200-1209	4.8	2
223	Expanding a Portfolio of (FO-) SPR Surface Chemistries with the Co(III)-NTA Oriented Immobilization of His-Tagged Bioreceptors for Applications in Complex Matrices. <i>ACS Sensors</i> , <b>2020</b> , 5, 960-969	9.2	11
222	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 734-755	6.1	45
221	DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure. <i>Molecular Therapy</i> , <b>2020</b> , 28, 1068-1077	11.7	10
220	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 35-64	4.4	29

219	Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2020</b> , 24, 102103	6	9
218	Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 681-692	15.4	8
217	Structural Insights into the Mechanism of a Nanobody That Stabilizes PAI-1 and Modulates Its Activity. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	5
216	Electroporation outperforms in vivo-jetPEI for intratumoral DNA-based reporter gene transfer. <i>Scientific Reports</i> , <b>2020</b> , 10, 19532	4.9	2
215	Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 622473	5.4	21
214	The rise of oncology biosimilars: from process to promise. <i>Future Oncology</i> , <b>2019</b> , 15, 3255-3265	3.6	3
213	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting. <i>BioDrugs</i> , <b>2019</b> , 33, 299-306	7.9	9
212	Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics <b>2019</b> , 7, 105		52
211	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting. <i>BioDrugs</i> , <b>2019</b> , 33, 285-297	7.9	17
210	Bridging the Clinical Gap for DNA-Based Antibody Therapy Through Translational Studies in Sheep. <i>Human Gene Therapy</i> , <b>2019</b> , 30, 1431-1443	4.8	9
209	The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 199-210	8.7	31
208	Demystifying biosimilars: development, regulation and clinical use. <i>Future Oncology</i> , <b>2019</b> , 15, 777-790	3.6	13
207	A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 298-308	7	7
206	Clearance of plasmin-PN-1 complexes by vascular smooth muscle cells in human aneurysm of the ascending aorta. <i>Cardiovascular Pathology</i> , <b>2018</b> , 32, 15-25	3.8	5
205	Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching. <i>Clinical Therapeutics</i> , <b>2018</b> , 40, 798-809.e2	3.5	16
204	Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2018</b> , 314, L54-L68	5.8	9
203	Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. <i>Blood</i> , <b>2018</b> , 132, 1593-1603	2.2	23
202	Prolonged expression and anti-tumor response of DNA-based anti-HER2 antibodies. <i>Oncotarget</i> , <b>2018</b> , 9, 13623-13636	3.3	16

201	Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196911	3.7	1
200	The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. <i>Drugs</i> , <b>2017</b> , 77, 671-677	12.1	73
199	Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 308-315	3.2	7
198	Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator. <i>Scientific Reports</i> , <b>2017</b> , 7, 3385	4.9	22
197	Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 2432-2442	15.4	10
196	The road from development to approval: evaluating the body of evidence to confirm biosimilarity. <i>Rheumatology</i> , <b>2017</b> , 56, iv4-iv13	3.9	13
195	Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1509-1517	7	2
194	State of play and clinical prospects of antibody gene transfer. <i>Journal of Translational Medicine</i> , <b>2017</b> , 15, 131	8.5	33
193	The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 314	5.6	56
192	Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 969-75	4.5	39
191	Biosimilarity Versus Manufacturing Change: Two Distinct Concepts. <i>Pharmaceutical Research</i> , <b>2016</b> , 33, 261-8	4.5	31
190	Importance of manufacturing consistency of the glycosylated monoclonal antibody adalimumab (Humira®) and potential impact on the clinical use of biosimilars. <i>GaBI Journal</i> , <b>2016</b> , 5, 70-73	3.1	5
189	Defective TAFI Activation in Hemophilia Exacerbates Vascular Remodeling in Hemophilic Arthropathy. <i>Blood</i> , <b>2016</b> , 128, 82-82	2.2	
188	Defective TAFI Activation in Hemophilia Worsens Joint Bleeding. <i>Blood</i> , <b>2016</b> , 128, 3752-3752	2.2	
187	Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 1032-1040	7	13
186	Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 537-43	7	9
185	Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 193	5.6	48
184	Prevention of Serpin Misfolding by RNA Aptamers. <i>Cell Chemical Biology</i> , <b>2016</b> , 23, 639-40	8.2	

183	A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 15156-68	5.4	26
182	Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 1629-38	15.4	13
181	Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice. <i>Stroke</i> , <b>2016</b> , 47, 2419-22	6.7	35
180	Selective neutralization of the serpin protease nexin-1 by a specific monoclonal antibody. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 631-3	4.5	
179	Biosimilars - terms of use. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 2325-30	2.5	12
178	Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2015</b> , 52, 429-37	5.7	23
177	Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 1084-9	15.4	4
176	Long-term in vivo expression of trastuzumab following intramuscular electrotransfer of the encoding DNA in mice <b>2015</b> , 3,		1
175	Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 479-85	3.2	36
174	Development of a liquid chromatography/mass spectrometry assay for the bacterial transglycosylation reaction through measurement of Lipid II. <i>Electrophoresis</i> , <b>2015</b> , 36, 2841-2849	3.6	2
173	Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke. <i>Blood</i> , <b>2015</b> , 125, 1325-32	2.2	41
172	The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 2540-8	4.5	8
171	Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays. <i>Thrombosis Research</i> , <b>2014</b> , 134, 1097-102	8.2	13
170	PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. <i>Nature Medicine</i> , <b>2014</b> , 20, 741-7	50.5	64
169	Novel or expanding current targets in fibrinolysis. <i>Drug Discovery Today</i> , <b>2014</b> , 19, 1476-82	8.8	19
168	Clot stability and fibrin deposition is strongly reduced in mice in which mouse TAFI is replaced by human TAFI. <i>Thrombosis Research</i> , <b>2014</b> , 133, 1166-8	8.2	
167	Effectiveness of the electronic cigarette: An eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaints. <i>International Journal of Environmental Research and Public Health</i> , <b>2014</b> , 11, 11220-48	4.6	138
166	Systemic inhibition and liver-specific over-expression of PAI-1 failed to improve survival in all-inclusive populations or homogenous cohorts of CLP mice. <i>Journal of Thrombosis and Haemostasis</i> , <b>2014</b> , 12, 958-69	15.4	7

165	Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application. <i>Journal of Thrombosis and Haemostasis</i> , <b>2014</b> , 12, 229-36	15.4	13
164	Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 669-73	3.2	36
163	In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 824-32	7	8
162	Prevention of Premature Fibrinolysis and Reduction of Bleeding in Vivo in Hemophilia with Inhibitors By a Stabilized TAFI Variant. <i>Blood</i> , <b>2014</b> , 124, 694-694	2.2	2
161	Plasmin and the thrombin-thrombomodulin complex both contribute to thrombin-activatable fibrinolysis inhibitor activation in whole blood model thrombi. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 190-2	15.4	10
160	Remarkable stabilization of plasminogen activator inhibitor 1 in a "molecular sandwich" complex. <i>Biochemistry</i> , <b>2013</b> , 52, 4697-709	3.2	12
159	Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2013</b> , 39, 365-72	5.3	21
158	Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2013</b> , 39, 356-64	5.3	98
157	Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 2137-47	15.4	17
156	Letter: dry blood spots for anti-TNF treatment monitoring in IBD. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 1024-5	6.1	7
155	Evaluation of the profibrinolytic properties of a bispecific antibody-based inhibitor against human and mouse thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 2069-71	15.4	7
154	Nebulized fibrinolytic agents improve pulmonary fibrinolysis but not inflammation in rat models of direct and indirect acute lung injury. <i>PLoS ONE</i> , <b>2013</b> , 8, e55262	3.7	15
153	Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 725-7	15.4	9
152	Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 1091-9	15.4	8
151	The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. <i>Thrombosis Research</i> , <b>2012</b> , 130, 576-85	8.2	83
150	Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. <i>Thrombosis Research</i> , <b>2012</b> , 129, e126-33	8.2	19
149	The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 2555-62	15.4	19
148	Immunological toolbox available for in situ exploration of pectic homogalacturonan and its modifying enzymes in fruits and vegetables and their derived food products. <i>Innovative Food Science and Emerging Technologies</i> , <b>2012</b> , 15, 72-80	6.8	1

147	A European perspective on the market accessibility of biosimilars. <i>Biosimilars (Auckland, New Zealand)</i> , <b>2012</b> , 33		27
146	Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2012</b> , 32, 427-33	9.4	37
145	Glycosylation influences the stability of human plasminogen activator inhibitor-1. <i>Blood Coagulation and Fibrinolysis</i> , <b>2012</b> , 23, 570-2	1	3
144	Development of an immunological toolbox to detect endogenous and exogenous pectin methylesterase in plant-based food products. <i>Food Research International</i> , <b>2011</b> , 44, 931-939	7	3
143	Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility. <i>Journal of Molecular Biology</i> , <b>2011</b> , 411, 417-29	6.5	11
142	High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. <i>Thrombosis Research</i> , <b>2011</b> , 127, 254-8	8.2	14
141	Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. <i>Thrombosis Research</i> , <b>2011</b> , 128, 68-76	8.2	13
140	Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 90-101	7	19
139	Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. <i>Biochemical Journal</i> , <b>2011</b> , 438, 39-51	3.8	14
138	Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. <i>Blood</i> , <b>2011</b> , 117, 4615-22	2.2	32
137	TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation. <i>Journal of Thrombosis and Haemostasis</i> , <b>2011</b> , 9, 2268-77	15.4	20
136	Advances in understanding pectin methylesterase inhibitor in kiwi fruit: an immunological approach. <i>Planta</i> , <b>2011</b> , 233, 287-98	4.7	10
135	Identification of a bacterial inhibitor against g-type lysozyme. <i>Cellular and Molecular Life Sciences</i> , <b>2011</b> , 68, 1053-64	10.3	40
134	Use of mouse models to study plasminogen activator inhibitor-1. <i>Methods in Enzymology</i> , <b>2011</b> , 499, 77-104	10.4	9
133	Urokinase-type plasminogen activator promotes paracellular transmigration of neutrophils via Mac-1, but independently of urokinase-type plasminogen activator receptor. <i>Circulation</i> , <b>2011</b> , 124, 1848-59	16.7	33
132	Thrombin activatable fibrinolysis inhibitor. <i>Hamostaseologie</i> , <b>2011</b> , 31, 165-6, 168-73	1.9	24
131	Biosimilars: controversies as illustrated by rhGH. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 1219-29.5	29.5	27
130	Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences. <i>Journal of Structural Biology</i> , <b>2010</b> , 171, 95-101	3.4	16

129	Monoclonal antibodies: indications, budget impact and use. <i>Journal of Pharmaceutical Health Services Research</i> , <b>2010</b> , 1, 123-130	1	1
128	Lysozyme inhibitor conferring bacterial tolerance to invertebrate type lysozyme. <i>Cellular and Molecular Life Sciences</i> , <b>2010</b> , 67, 1177-88	10.3	32
127	Plant pectin methylesterase and its inhibitor from kiwi fruit: Interaction analysis by surface plasmon resonance. <i>Food Chemistry</i> , <b>2010</b> , 121, 207-214	8.5	19
126	Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 1302-12	15.4	36
125	Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1). <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 102, 609-10	7	8
124	Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 102, 69-75	7	6
123	The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 7059-67	5.4	23
122	Development and evaluation of monoclonal antibodies as probes to assess the differences between two tomato pectin methylesterase isoenzymes. <i>Journal of Immunological Methods</i> , <b>2009</b> , 349, 18-27	2.5	11
121	Effect of Reteplase and PAI-1 antibodies on postoperative adhesion formation in a laparoscopic mouse model. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2009</b> , 23, 1018-25	5.2	6
120	Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2009</b> , 7, 49-57	15.4	156
119	The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2009</b> , 7, 919-27	15.4	58
118	High quality structure of cleaved PAI-1-stab. <i>Journal of Structural Biology</i> , <b>2009</b> , 165, 126-32	3.4	14
117	Conformational (in)stability of rat vs. human activated thrombin activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 1426-8	15.4	3
116	Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 1892-9	15.4	20
115	Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 1884-91	15.4	16
114	Redirection of the reaction between activated protein C and a serpin to the substrate pathway. <i>Thrombosis Research</i> , <b>2008</b> , 122, 397-404	8.2	11
113	A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. <i>Molecular Pharmacology</i> , <b>2008</b> , 74, 641-53	4.3	21
112	Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. <i>Circulation Research</i> , <b>2008</b> , 102, 295-301	15.7	21



111	Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 268-76	15.4	10
110	Biotherapeutics in the era of biosimilars: what really matters is patient safety. <i>Drug Safety</i> , <b>2007</b> , 30, 1087-92	5.1	14
109	Announcing a TAFIa mutant with a 180-fold increased half-life and concomitantly a strongly increased antifibrinolytic potential. <i>Journal of Thrombosis and Haemostasis</i> , <b>2007</b> , 5, 418-20	15.4	22
108	Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. <i>Journal of Thrombosis and Haemostasis</i> , <b>2007</b> , 5, 1500-8	15.4	26
107	Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability. <i>Journal of Thrombosis and Haemostasis</i> , <b>2007</b> , 5, 2105-12	15.4	14
106	Study of recombinant antibody fragments and PAI-1 complexes combining protein-protein docking and results from site-directed mutagenesis. <i>Structure</i> , <b>2007</b> , 15, 1105-16	5.2	7
105	Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 26306-15	5.4	15
104	Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 955-62	9.4	60
103	Comparison of random and oriented immobilisation of antibody fragments on mixed self-assembled monolayers. <i>Journal of Immunological Methods</i> , <b>2006</b> , 312, 167-81	2.5	126
102	Development of ELISAs measuring the extent of TAFI activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2006</b> , 26, 423-8	9.4	36
101	Plasminogen activator inhibitor-1 modulates adipocyte differentiation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2006</b> , 290, E103-E113	6	92
100	Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 36071-81	5.4	34
99	Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 15878-83	5.4	26
98	Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)--a comparative study assessing the biological equivalence of rat, murine and human TAFI. <i>Journal of Thrombosis and Haemostasis</i> , <b>2006</b> , 4, 2470-7	15.4	22
97	Quantitation of Vervet Monkey ( <i>Chlorocebus aethiops</i> ) plasminogen activator inhibitor-1 in plasma and platelets. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 902-903	7	5
96	Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: prothrombotic response of drug-eluting or bare stent implantation within the first 24 hours. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 96, 202-9	7	15
95	Quantitation of Vervet monkey ( <i>Chlorocebus aethiops</i> ) plasminogen activator inhibitor-1 in plasma and platelets. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 902-3	7	2
94	Function-stabilizing mechanism of plasminogen activator inhibitor type 1 induced upon binding to alpha1-acid glycoprotein. <i>Biochemistry</i> , <b>2005</b> , 44, 12384-90	3.2	14

93	The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event. <i>Biophysical Journal</i> , <b>2005</b> , 88, 2848-54	2.9	8
92	Modulation of TAFI function through different pathways—implications for the development of TAFI inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , <b>2005</b> , 3, 2745-53	15.4	40
91	His374 of wheat endoxylanase inhibitor TAXI-I stabilizes complex formation with glycoside hydrolase family 11 endoxylanases. <i>FEBS Journal</i> , <b>2005</b> , 272, 5872-82	5.7	28
90	Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 1482-9	5.4	18
89	Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion. <i>Thrombosis and Haemostasis</i> , <b>2004</b> , 91, 497-505	7	13
88	The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. <i>Thrombosis and Haemostasis</i> , <b>2004</b> , 91, 425-37	7	79
87	Plasminogen activator inhibitor-1. <i>Current Medicinal Chemistry</i> , <b>2004</b> , 11, 2323-34	4.3	58
86	Site-directed targeting of plasminogen activator inhibitor-1 as an example for a novel approach in rational drug design. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 20447-50	5.4	3
85	Protonation state of a single histidine residue contributes significantly to the kinetics of the reaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 23007-13	5.4	6
84	Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2004</b> , 2, 780-4	15.4	15
83	Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI-1 inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , <b>2004</b> , 2, 289-97	15.4	6
82	Inhibition of plasminogen activator inhibitor-1: antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs. <i>Journal of Thrombosis and Haemostasis</i> , <b>2004</b> , 2, 298-305	15.4	12
81	Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. <i>Oncogene</i> , <b>2004</b> , 23, 6986-90	9.2	133
80	The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?. <i>Thrombosis and Haemostasis</i> , <b>2004</b> , 92, 898-924	7	24
79	Realization and characterization of porous gold for increased protein coverage on acoustic sensors. <i>Analytical Chemistry</i> , <b>2004</b> , 76, 4299-306	7.8	106
78	Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 321, 746-51	3.4	1
77	Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional properties. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 23899-905	5.4	12
76	Development of a genotype 325-specific proCPU/TAFI ELISA. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, 1122-7	9.4	76

75	Biochemical importance of glycosylation of plasminogen activator inhibitor-1. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 90, 206-17	7	42
74	Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 89, 74-82	7	5
73	Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 90, 52-58	7	23
72	Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. <i>Investigative Ophthalmology and Visual Science</i> , <b>2003</b> , 44, 2791-7		43
71	Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1. <i>Journal of Thrombosis and Haemostasis</i> , <b>2003</b> , 1, 1028-33	15.4	17
70	Structural determinants in the stability of the serpin/proteinase complex. <i>Biochemical and Biophysical Research Communications</i> , <b>2003</b> , 307, 529-34	3.4	4
69	Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1. <i>Biophysical Journal</i> , <b>2003</b> , 85, 501-10	2.9	13
68	Plasminogen Activators Inhibitors <b>2003</b> , 47-66		1
67	Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. <i>Cancer Research</i> , <b>2003</b> , 63, 1500-7	10.1	53
66	Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 90, 52-8	7	7
65	Characterization and Comparative Evaluation of a Novel PAI-1 Inhibitor. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 137-143	7	28
64	Importance of N-Terminal Residues in Plasminogen Activator Inhibitor 1 on its Antibody Induced Latency Transition. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 288-293	7	16
63	Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 43858-65	5.4	29
62	Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. <i>Circulation</i> , <b>2002</b> , 106, 491-6	16.7	148
61	The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. <i>FASEB Journal</i> , <b>2002</b> , 16, 147-54	0.9	238
60	Enhanced expression of plasminogen activator inhibitor-1 by dedifferentiated thyrocytes. <i>Biochemical and Biophysical Research Communications</i> , <b>2002</b> , 295, 737-43	3.4	11
59	Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes. <i>Journal of Cellular Physiology</i> , <b>2001</b> , 189, 72-8	7	27
58	Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1. <i>Protein Science</i> , <b>2001</b> , 10, 798-808	6.3	38

57	The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 44912-8	5.4	29
56	Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 26243-8	5.4	16
55	The importance of helix F in plasminogen activator inhibitor-1. <i>BBA - Proteins and Proteomics</i> , <b>2000</b> , 1476, 20-6		20
54	Immunoassays for the Quantitation of Porcine PAI-1 Antigen and Activity in Biological Fluid Samples. <i>Thrombosis and Haemostasis</i> , <b>2000</b> , 84, 1082-1086	7	5
53	Effect of Stabilizing versus Destabilizing Interactions on Plasminogen Activator Inhibitor-1. <i>Thrombosis and Haemostasis</i> , <b>2000</b> , 84, 871-875	7	21
52	Prevention of Renal Fibrin Deposition in Endotoxin-induced DIC through Inhibition of PAI-1. <i>Thrombosis and Haemostasis</i> , <b>2000</b> , 84, 65-70	7	49
51	Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 37645-50	5.4	47
50	Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 6375-80	5.4	46
49	Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. <i>Journal of Molecular Biology</i> , <b>2000</b> , 297, 683-95	6.5	90
48	Glycosylation dependent conformational transitions in plasminogen activator inhibitor-1: evidence for the presence of two active conformations. <i>Fibrinolysis and Proteolysis</i> , <b>2000</b> , 14, 58-64		6
47	Immunological Quantitation of Rabbit Plasminogen Activator Inhibitor-1 in Biological Samples. <i>Thrombosis and Haemostasis</i> , <b>1999</b> , 82, 1510-1515	7	8
46	Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 17511-7	5.4	53
45	Plasminogen activator inhibitor 1 (PAI-1) in its active conformation: crystallization and preliminary X-ray diffraction data. <i>Acta Crystallographica Section D: Biological Crystallography</i> , <b>1999</b> , 55, 574-6		3
44	Induction of conformational changes within crystals of plasminogen activator inhibitor-1 (PAI-1). <i>Fibrinolysis and Proteolysis</i> , <b>1999</b> , 13, 203-207		2
43	Hormonal Control of Plasminogen Activator Inhibitor-1 Gene Expression and Production in Human Adipose Tissue: Stimulation by Glucocorticoids and Inhibition by Catecholamines. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 4097-4105	5.6	64
42	Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: evidence that the P13 residue contributes significantly to the active to substrate transition. <i>BBA - Proteins and Proteomics</i> , <b>1998</b> , 1387, 291-7		9
41	Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. <i>Kidney International</i> , <b>1998</b> , 54, 1324-30	9.9	31
40	Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant. <i>Fibrinolysis and Proteolysis</i> , <b>1998</b> , 12, 277-282		17

39	Suppression of plasminogen activator inhibitor 1 (PAI-1) activity levels in rats by monoclonal antibodies. <i>Fibrinolysis and Proteolysis</i> , <b>1998</b> , 12, 335-339		4
38	Identification of a Functional Epitope in Plasminogen Activator Inhibitor-1, not Localized in the Reactive Center Loop. <i>Thrombosis and Haemostasis</i> , <b>1998</b> , 79, 597-601	7	28
37	Modulation of Plasminogen Activator Inhibitor 1 by Triton X-100 Identification of Two Consecutive Conformational Transitions. <i>Thrombosis and Haemostasis</i> , <b>1998</b> , 80, 286-291	7	53
36	Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 12662-6	5.4	32
35	Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases. <i>Journal of Structural Biology</i> , <b>1997</b> , 118, 236-42	3.4	15
34	Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1. <i>FEBS Letters</i> , <b>1997</b> , 415, 192-5	3.8	16
33	Identification of functional synergism between monoclonal antibodies. Application to the enhancement of plasminogen activator inhibitor-1 neutralizing effects. <i>FEBS Letters</i> , <b>1997</b> , 416, 373-6	3.8	7
32	Expression, purification, and characterization of recombinant rat plasminogen activator inhibitor-1. <i>Fibrinolysis and Proteolysis</i> , <b>1997</b> , 11, 37-43		5
31	Construction and characterization of plasminogen activator inhibitor-1 mutants in which part of the active site loop is deleted. <i>Fibrinolysis and Proteolysis</i> , <b>1997</b> , 11, 265-271		2
30	Cloning of a single-chain variable fragment (scFv) switching active plasminogen activator inhibitor-1 to substrate. <i>Gene</i> , <b>1997</b> , 189, 83-8	3.8	12
29	Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. <i>BBA - Proteins and Proteomics</i> , <b>1997</b> , 1337, 257-66		63
28	Bioavailability of different artemisinin tablet formulations in rabbit plasma--correlation with results obtained by an in vitro dissolution method. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>1997</b> , 16, 185-9	3.5	10
27	Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. <i>Biochemistry</i> , <b>1996</b> , 35, 7474-81	3.2	76
26	Various approaches to standardization and the importance of measurement accuracy. <i>Fibrinolysis</i> , <b>1996</b> , 10, 113-116		
25	Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. <i>Circulation</i> , <b>1996</b> , 94, 197-206	16.7	46
24	Crystallization and X-ray diffraction data of the cleaved form of plasminogen activator inhibitor-1. <i>Proteins: Structure, Function and Bioinformatics</i> , <b>1995</b> , 23, 118-21	4.2	22
23	Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. <i>Nature Structural Biology</i> , <b>1995</b> , 2, 891-7		99
22	Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 8397-400	5.4	44

21	Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. <i>Biochemistry</i> , <b>1995</b> , 34, 1064-9	3.2	53
20	Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. <i>FEBS Letters</i> , <b>1995</b> , 376, 243-6	3.8	24
19	Pathophysiology of fibrinolysis. <i>Best Practice and Research: Clinical Haematology</i> , <b>1995</b> , 8, 329-43		19
18	Immunoassay of Murine t-PA, u-PA and PAI-1 Using Monoclonal Antibodies Raised in Gene-inactivated Mice. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 74, 1305-1309	7	73
17	An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function. <i>British Journal of Haematology</i> , <b>1994</b> , 87, 562-71	4.5	32
16	A model of the reactive form of plasminogen activator inhibitor-1. <i>Journal of Structural Biology</i> , <b>1994</b> , 113, 239-45	3.4	24
15	Immunological methods to study the fibrinolytic system. <i>Fibrinolysis</i> , <b>1993</b> , 7, 9-10		5
14	Influence of oral intake of retinoids on the human plasma fibrinolytic system. <i>Fibrinolysis</i> , <b>1993</b> , 7, 347-351		8
13	Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1). <i>BBA - Proteins and Proteomics</i> , <b>1993</b> , 1202, 221-9		24
12	Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. <i>Fibrinolysis</i> , <b>1992</b> , 6, 232-242		51
11	Induction of t-PA Synthesis with intravenous bolus injection of vitamin A palmitate in vitamin a deficient rats. <i>Fibrinolysis</i> , <b>1992</b> , 6, 243-249		8
10	An Enzyme-Linked Immunosorbent Assay for Urokinase-Type Plasminogen Activator (u-PA) and Mutants and Chimeras Containing the Serine Protease Domain of u-PA. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 67, 095-100	7	18
9	Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. <i>Thrombosis Research</i> , <b>1991</b> , 62, 275-85	8.2	15
8	Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. <i>Thrombosis Research</i> , <b>1990</b> , 60, 509-16	8.2	44
7	Measurement of different forms of plasminogen activator inhibitor 1(PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays. <i>Fibrinolysis</i> , <b>1990</b> , 4, 132-133		17
6	Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. <i>Journal of Clinical Investigation</i> , <b>1989</b> , 84, 586-91	15.9	30
5	Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). <i>FEBS Journal</i> , <b>1988</b> , 175, 531-40		65
4	Hydrogenosomal ATP:AMP phosphotransferase of <i>Trichomonas vaginalis</i> . <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , <b>1987</b> , 88, 575-80		8

- 3 Polarographic evidence for the interaction of reduced nitroimidazole derivatives with DNA bases. *Journal of the Chemical Society Faraday Transactions I*, **1987**, 83, 257 21
- 2 In vitro reductive activation of nitroimidazoles. *Biochemical Pharmacology*, **1986**, 35, 59-61 6 34
- 1 Base specific interaction of reductively activated nitroimidazoles with DNA. *FEBS Letters*, **1983**, 164, 145-88 22